testing JJCTF

Test 123

[C10H12N2]

 STINK TO HIGH HEAVEN



IMO, only a fool would continue sitting on their hands and knees watching their chances at a decent ROI slip away because of ongoing shenanigans @ virtual office HQ. What further shenanigans do you need to endure before taking action, another 100 to 1 reverse split in 2023?

CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
[e-mail]
[e-mail]
www.algernonpharmaceuticals.com

I will reiterate once again, your chances of getting any significant ROI will come down to what decision management makes with the proceeds from the Public Offering. If they decide to barrel ahead with Phase 1 studies you are toast for at least the next 5 years. If they do the right and obvious thing, they will take the money and run a Gold Standard Phase 2 study for Chronic Cough in the USA ASAP.

Chronic Cough is the fast track to a billion dollar market cap. Moreau cannot point to any other faster avenue if one even exists with Cancer or Stroke or CKD. They're all long shots far off into the distant future. Chronic Cough is here and now. Strike while the iron is hot (momentum and market interest) and finally give Bellus Health a run for the money versus blowing hot are on webcast claiming Bellus Health is a pure comparison to Algernon Pharmaceuticals.

Prove it in Words and Deeds Christopher Moreau (CEO).

Good Luck To All In All Your Endeavors In Life,

M$